Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 707 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IT Injection Clear all
Active, not recruiting Phase 1 Interventional

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

NCT03152318
View directory record Official record
Conditions
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
Interventions
rQNestin, Cyclophosphamide, Stereotactic biopsy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Early Phase 1 Interventional Results available

Examining Bioactivity of PVSRIPO in Invasive Breast Cancer

NCT03564782
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
PVSRIPO
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

NCT02927964
View directory record Official record
Conditions
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Interventions
Ibrutinib, Radiation Therapy, TLR9 Agonist SD-101
Drug · Radiation
Lead sponsor
Robert Lowsky
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

NCT04020185
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy
Drug
Lead sponsor
ImmuneSensor Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • La Jolla, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 21, 2026, 1:46 PM EDT
Completed No phase listed Observational

Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis

NCT04676555
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Ocrelizumab, Ofatumumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 21, 2026, 1:46 PM EDT
Not listed Phase 2 Interventional

Ultrasound-Guided Treatments for Shoulder Pain in Wheelchair Users With Spinal Cord Injury

NCT04136743
View directory record Official record
Conditions
Spinal Cord Injuries, Tendinopathy, Rotator Cuff Tears, Shoulder Pain
Interventions
Lipogems, Dexamethasone
Device · Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 21, 2026, 1:46 PM EDT
Enrolling by invitation Phase 4 Interventional

DaTSCAN Imaging in Aging and Neurodegenerative Disease

NCT01453127
View directory record Official record
Conditions
Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
Interventions
I-123 Ioflupane solution injection prior to SPECT scan (DaTscan), Single photon emission computed tomography (SPECT) scan
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Suprazygomatic Maxillary Nerve Block in Cleft Palate Outcomes

NCT04909619
View directory record Official record
Conditions
Cleft Palate Children
Interventions
Ultrasound-guided bilateral suprazygomatic maxillary nerve block, Local anesthetic infiltration of the palate
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
9 Months to 2 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 21, 2026, 1:46 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

PRP vs PRP Plus IGF for Patellar Tendinosis

NCT04350827
View directory record Official record
Conditions
Tendinopathy, Patellar Ligament, Platelet-Rich Plasma
Interventions
Platelet Rich Plasma, Platelet Rich Plasma plus IGF
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Not applicable Interventional

Enhancement of Contrast Opacification for Echocardiographic Imaging of the Right Heart and Shunts

NCT02661529
View directory record Official record
Conditions
Bidirectional Cardiovascular Shunt
Interventions
Transesophageal Echocardiogram (TEE), Transthoracic Echocardiogram (TTE), Saline/Air Mixture, Saline/Blood Mixture
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 105 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare Ultrasound Assisted Cold Therapy and Lidocaine Injection to Treat Morton's Neuroma

NCT02838758
View directory record Official record
Conditions
Intermetatarsal Neuroma
Interventions
Cryoablation, Lidocaine, Saline
Device · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 3 Interventional

Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial

NCT00639106
View directory record Official record
Conditions
Breast Cancer
Interventions
Alloderm, Questionnaires, Without ALLODERM, Questionnaires
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
3
States / cities
Ann Arbor, Michigan • New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 21, 2026, 1:46 PM EDT
Terminated Not applicable Interventional Results available

Study to Evaluate Safety & Effectiveness of Vascular Sealant System

NCT00439309
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Gelfoam/Thrombin, VascuSeal
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Not applicable Interventional

Effect of Beet Juice Supplementation on Vascular and Inspiratory Muscle Function

NCT04920799
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Nitrate rich beetroot juice, Nitrate depleted beetroot juice
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
60 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

NCT04811664
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Moderna COVID-19 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 29 Years
Enrollment
1,923 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
51
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Beetroot Juice on Blood Pressure Regulation in Post Menopausal Women

NCT03380000
View directory record Official record
Conditions
Postmenopausal Women
Interventions
Beetroot juice, Beetroot juice placebo
Drug
Lead sponsor
Penn State University
Other
Eligibility
55 Years to 80 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

Endoscopic Gastric Reduction for Weight Management

NCT01682733
View directory record Official record
Conditions
Obesity
Interventions
Botulinum toxin, Overstitch Endoscopic Suturing System
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 21, 2026, 1:46 PM EDT
Recruiting Phase 3 Interventional

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244
View directory record Official record
Conditions
Acute Ischemic Stroke, Cerebral Stroke
Interventions
Drug: Normal Saline, Sovateltide
Drug
Lead sponsor
Pharmazz, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 21, 2026, 1:46 PM EDT
Terminated Phase 2 Interventional Results available

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

NCT02518750
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
Interventions
Dexamethasone, Panobinostat, Liposomal vincristine, Mitoxantrone, Peg-asparaginase, Bortezomib, Intrathecal Triples, High-dose methotrexate, 6-Mercaptopurine, High-dose cytarabine, Nelarabine, Cyclophosphamide, Etoposide, Clofarabine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 21, 2026, 1:46 PM EDT
Terminated Phase 3 Interventional Results available

Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System

NCT03643562
View directory record Official record
Conditions
Niemann-Pick Type C Disease
Interventions
Adrabetadex
Drug
Lead sponsor
Mandos LLC
Industry
Eligibility
4 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

Acupuncture for Low-Dose Opioid for TKA Replacement

NCT04084288
View directory record Official record
Conditions
Knee Osteoarthritis, Pain, Postoperative, Acupuncture
Interventions
Acupuncture, Peripheral Nerve Stimulator
Other · Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 21, 2026, 1:46 PM EDT
Terminated Phase 1 Interventional

Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine

NCT00074607
View directory record Official record
Conditions
Meningitis, Neoplasms
Interventions
Gemcitabine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
5
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

NCT00288704
View directory record Official record
Conditions
Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
Interventions
rilonacept 160 mg, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
24
States / cities
Little Rock, Arkansas • Palm Desert, California • Upland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 21, 2026, 1:46 PM EDT